Speculating in Takeover Targets Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Speculating in Takeover Targets

ULBI 6.443

+1.5%

3:58 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: richardred who started this subject	7/25/2003 10:59:12 AM
From: richardred	Read Replies (1) of 7265

Billion plus merger in bio-(Who's Next in Bio ?)-Lots of cash on the sidelines by big drugs- IMO- the Biogen/IDPH merger has a good chance of falling apart-Maybe Roche will pay the breakup fee here and save IDPH? Igen International (IGEN: news, chart, profile) soared more than 53 percent after Swiss pharmaceutical giant Roche announced late Thursday that it would pay about $1.4 billion to secure the rights to technology owned by the company. In a complex transaction, Roche said it would pay $47.25 per share, or $1.26 billion, in cash to acquire Gaithersburg, Md.-based Igen. Igen shareholders would also get shares in a new company that would be spun off and run by Igen's current management. Roche will provide the new company, yet to be named, with about $155 million.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next